Patents by Inventor Steven D. Leach

Steven D. Leach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210277454
    Abstract: The present disclosure relates to an array-based assay for transposase-accessible chromatin and prognostic molecular markers of treatment-resistant/early recurrent cancer. The present disclosure also relates to predicting an outcome, such as duration of disease-free survival, in a cancer patient.
    Type: Application
    Filed: May 18, 2021
    Publication date: September 9, 2021
    Inventors: Surajit Dhara, Steven D. Leach, Sagar Chhangawala, Christina Leslie
  • Publication number: 20200232040
    Abstract: Systems and methods for determining the likely responsiveness of a human cancer subject to a checkpoint blockade immunotherapy regimen are provided. Sequencing reads are obtained from samples from the subject representative of the cancer. A human leukocyte antigen type and a plurality of clones is determined from the sequencing reads. For each clone, an initial frequency X? in the one or more samples is determined and a corresponding clone fitness score of the clone is computed, thereby computing clone fitness scores. Each such fitness score is computed by identifying neoantigens in the respective clone, computing a recognition potential for each neoantigen, and determining the corresponding clone fitness score of the respective clone as an aggregate of these recognition potentials. A total fitness, quantifying the likely responsiveness of the subject to the regimen, is computed by summing the clone fitness scores across the plurality of clones.
    Type: Application
    Filed: January 18, 2018
    Publication date: July 23, 2020
    Inventors: Marta Luksza, Vinod P. Balachandran, Arnold J. Levin, Jedd D. Wolchok, Taha Merghoub, Steven D. Leach, Timothy A. Chan, Benjamin D. Greenbaum, Michael Laessig
  • Patent number: 10156521
    Abstract: A detectable substrate for aldehyde dehydrogenase (ALDH) can be used for selecting cells that express ALDH. The detectable substrate can have a fluorescent moiety that has an excitation wavelength, an emission wavelength, or both, that does not overlap with the excitation wavelength, emission wavelength, or both, of green fluorescent protein.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: December 18, 2018
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Haofan Wang, Il Minn, Steven D. Leach, Ronnie C. Mease
  • Publication number: 20150369738
    Abstract: A detectable substrate for aldehyde dehydrogenase (ALDH) can be used for selecting cells that express ALDH. The detectable substrate can have a fluorescent moiety that has an excitation wavelength, an emission wavelength, or both, that does not overlap with the excitation wavelength, emission wavelength, or both, of green fluorescent protein.
    Type: Application
    Filed: February 21, 2014
    Publication date: December 24, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, HAOFAN WANG, IL MINN, STEVEN D. LEACH, RONNIE C. MEASE
  • Publication number: 20140017207
    Abstract: The present invention relates to the field of pancreatic progenitor cells. More specifically, the present invention provides methods for isolating self-renewing centroacinar and terminal ductal progenitors from adult human pancreas. In a specific embodiment, the method comprises the steps of (a) providing a population of pancreatic cells; and (b) selecting for high expression of CD133, EpCAM, and CD44 on the pancreatic cells to isolate self-renewing centroacinar and terminal ductal progenitors.
    Type: Application
    Filed: July 12, 2013
    Publication date: January 16, 2014
    Applicant: The Johns Hopkins University
    Inventors: Steven D. Leach, Meritxell Rovira-Clusellas